NCT04484779View on ClinicalTrials.gov

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions
Type 1 DiabetesType 2 Diabetes
Interventions
DEVICE

IIM System

IIM System

DRUG

Insulin Lispro and/or Insulin Glargine

Administered subcutaneously (SC)

Trial Locations (5)

72211

Medical Investigations Inc., Little Rock

78681

Texas Diabetes & Endocrinology, P.A., Round Rock

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Renton

78731-4309

Texas Diabetes & Endocrinology, P.A., Austin

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04484779 - A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes | Biotech Hunter | Biotech Hunter